{"filing":{"accession_number":"0001628280-26-045744","cik":"0001842952","ticker":"CNTX","company_name":"Context Therapeutics Inc.","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"cntx-20260624.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1842952/000162828026045744/cntx-20260624.htm"},"events":[{"id":14235,"run_id":12660,"accession_number":"0001628280-26-045744","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Context Therapeutics held its 2026 Annual Meeting of Stockholders, at which shareholders voted on and approved the election of seven directors, ratification of CohnReznick LLP as independent auditor, approval of a certificate amendment to increase authorized common shares from 200 million to 300 million, and approval of meeting adjournment.","company_name":"Context Therapeutics Inc.","ticker":"CNTX","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":[{"id":11604,"accession_number":"0001628280-26-045744","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure reports a stockholder-approved amendment to the Certificate of Incorporation increasing authorized common shares from 200 million to 300 million. While a governance matter, the increase in authorized shares is a routine administrative action that does not materially affect the registrant's financial condition, operations, or investor risk profile absent evidence of imminent dilutive issuance. The amendment itself is procedural and does not constitute a material event under securities law.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:12:01.316007+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11605,"accession_number":"0001628280-26-045744","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final voting results from Context Therapeutics' 2026 Annual Meeting of Stockholders, including election of seven directors, ratification of CohnReznick LLP as independent auditor, approval of a certificate amendment to increase authorized shares from 200 million to 300 million, and approval of meeting adjournment. The detailed vote tallies for each proposal are material to investors assessing board composition and capital structure changes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:12:01.316007+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11604,"accession_number":"0001628280-26-045744","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure reports a stockholder-approved amendment to the Certificate of Incorporation increasing authorized common shares from 200 million to 300 million. While a governance matter, the increase in authorized shares is a routine administrative action that does not materially affect the registrant's financial condition, operations, or investor risk profile absent evidence of imminent dilutive issuance. The amendment itself is procedural and does not constitute a material event under securities law.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:12:01.316007+00:00","company_name":"Context Therapeutics Inc.","ticker":"CNTX","filing_date":"2026-06-26"},{"id":11605,"accession_number":"0001628280-26-045744","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final voting results from Context Therapeutics' 2026 Annual Meeting of Stockholders, including election of seven directors, ratification of CohnReznick LLP as independent auditor, approval of a certificate amendment to increase authorized shares from 200 million to 300 million, and approval of meeting adjournment. The detailed vote tallies for each proposal are material to investors assessing board composition and capital structure changes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:12:01.316007+00:00","company_name":"Context Therapeutics Inc.","ticker":"CNTX","filing_date":"2026-06-26"}]}